Coronavirus disease-19 pneumonia: The impact of coagulopathy
Revista Mexicana de Angiologia
; 48(2):35-37, 2020.
Article
in English
| EMBASE | ID: covidwho-1737535
ABSTRACT
The development of coagulopathy is emerging as one of the most significant poor prognostic features in coronavirus disease (COVID)-19 pneumopathy. D-dimer, a protein product of fibrin degradation, has been found elevated in the most severe cases and correlated to mortality. Potentially involved factors in the impairment of coagulation caused by viral infection include the dysregulated inflammatory response, platelet, and endothelial dysfunction with impaired fibrinolysis. Heparin is an anticoagulant molecule that also showed anti-inflammatory properties and a potential antiviral effect. The use of low-molecular-weight heparin could prevent thromboembolic complications in COVID-19 pneumopathy. However, the correct timing of prophylaxis according to the stage of COVID-19 disease and the appropriate therapeutic dosage to use in severe cases needs further researches.
antiviral activity; article; blood clotting disorder; complication; coronavirus disease 2019; endothelial dysfunction; fibrinolysis; human; inflammation; lung disease; mortality; pneumonia; prevention; prophylaxis; therapeutic dose; thrombocyte dysfunction; thromboembolism; thrombosis; anticoagulant agent; D dimer; heparin; low molecular weight heparin
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
Language:
English
Journal:
Revista Mexicana de Angiologia
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS